Suppr超能文献

阿戈美拉汀所致肝损伤的系统评价。

A systematic review of agomelatine-induced liver injury.

作者信息

Freiesleben Silka Dawn, Furczyk Karolina

机构信息

Department of Psychiatry, University of Rostock, Gehlsheimerstraße 20, 18147 Rostock, Germany.

出版信息

J Mol Psychiatry. 2015 Apr 21;3(1):4. doi: 10.1186/s40303-015-0011-7. eCollection 2015.

Abstract

Agomelatine is an antidepressant with a unique mechanism of action. Since its marketing in 2009, concerns have been raised regarding its potential to induce liver injury. The authors therefore address the need to comprehensively evaluate the potential risk posed by agomelatine of inducing liver injury by reviewing data from published and unpublished clinical trials in both the pre- and postmarketing settings, as well as data from non-interventional studies, pharmacovigilance database reviews and one case report. Recommendations for clinicians are also provided. In this review, agomelatine was found to be associated with higher rates of liver injury than both placebo and the four active comparator antidepressants used in the clinical trials for agomelatine, with rates as high as 4.6% for agomelatine compared to 2.1% for placebo, 1.4% for escitalopram, 0.6% for paroxetine, 0.4% for fluoxetine, and 0% for sertraline. The review also provides evidence for the existence of a positive relationship between agomelatine dose and liver injury. Furthermore, rates of liver injury were found to be lower in non-interventional studies. Findings from pharmacovigilance database reviews and one case report also highlight the risk of agomelatine-induced liver injury. As agomelatine does pose a risk of liver injury, clinicians must carefully monitor liver function throughout treatment. However, agomelatine's unique mechanism of action and favourable safety profile render it a valuable treatment option. A quantitative analysis of agomelatine-induced liver injury is lacking in the literature and would be welcomed.

摘要

阿戈美拉汀是一种作用机制独特的抗抑郁药。自2009年上市以来,人们对其诱发肝损伤的可能性表示担忧。因此,作者通过回顾上市前和上市后已发表及未发表的临床试验数据、非干预性研究数据、药物警戒数据库审查数据以及一份病例报告,来全面评估阿戈美拉汀诱发肝损伤的潜在风险。文中还为临床医生提供了相关建议。在本次综述中,发现阿戈美拉汀诱发肝损伤的发生率高于安慰剂以及阿戈美拉汀临床试验中使用的四种活性对照抗抑郁药,阿戈美拉汀诱发肝损伤的发生率高达4.6%,而安慰剂为2.1%,艾司西酞普兰为1.4%,帕罗西汀为0.6%,氟西汀为0.4%,舍曲林为0%。该综述还为阿戈美拉汀剂量与肝损伤之间存在正相关关系提供了证据。此外,在非干预性研究中肝损伤发生率较低。药物警戒数据库审查结果和一份病例报告也突出了阿戈美拉汀诱发肝损伤的风险。由于阿戈美拉汀确实存在肝损伤风险,临床医生在整个治疗过程中必须仔细监测肝功能。然而,阿戈美拉汀独特的作用机制和良好的安全性使其成为一种有价值的治疗选择。目前文献中缺乏对阿戈美拉汀诱发肝损伤的定量分析,这方面的研究将受到欢迎。

相似文献

1
A systematic review of agomelatine-induced liver injury.
J Mol Psychiatry. 2015 Apr 21;3(1):4. doi: 10.1186/s40303-015-0011-7. eCollection 2015.
3
Antidepressant-induced liver injury: a review for clinicians.
Am J Psychiatry. 2014 Apr;171(4):404-15. doi: 10.1176/appi.ajp.2013.13050709.
4
Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.
CNS Drugs. 2015 Aug;29(8):695-712. doi: 10.1007/s40263-015-0267-6.
5
Publication bias and outcome reporting bias: agomelatine as a case example.
J Psychosoc Nurs Ment Health Serv. 2011 Sep;49(9):11-4. doi: 10.3928/02793695-20110809-01. Epub 2011 Aug 17.
7
Second-generation antidepressants for preventing seasonal affective disorder in adults.
Cochrane Database Syst Rev. 2015 Nov 8(11):CD011268. doi: 10.1002/14651858.CD011268.pub2.
8
Agomelatine's antiglycoxidative action- and research and systematic literature review.
Front Psychiatry. 2023 Apr 25;14:1164459. doi: 10.3389/fpsyt.2023.1164459. eCollection 2023.
10
CYP1A2 polymorphism may contribute to agomelatine-induced acute liver injury: Case report and review of the literature.
Medicine (Baltimore). 2021 Nov 12;100(45):e27736. doi: 10.1097/MD.0000000000027736.

引用本文的文献

1
Ameliorative effects of agomelatine against doxorubicin-induced hepatotoxicity.
BMC Pharmacol Toxicol. 2025 Aug 8;26(1):146. doi: 10.1186/s40360-025-00988-y.
2
Metabolic bioactivation of antidepressants: advance and underlying hepatotoxicity.
Drug Metab Rev. 2024 Feb-May;56(2):97-126. doi: 10.1080/03602532.2024.2313967. Epub 2024 Feb 20.
5
Experimental Data on the Role of Melatonin in the Pathogenesis of Nonalcoholic Fatty Liver Disease.
Biomedicines. 2023 Jun 15;11(6):1722. doi: 10.3390/biomedicines11061722.
6
Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders.
Brain Sci. 2023 Apr 27;13(5):734. doi: 10.3390/brainsci13050734.
7
Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery.
Pharmaceutics. 2023 Feb 23;15(3):746. doi: 10.3390/pharmaceutics15030746.
8
Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action.
Ther Adv Psychopharmacol. 2022 Jun 30;12:20451253221105128. doi: 10.1177/20451253221105128. eCollection 2022.
9
Agomelatine Exerts an Anti-inflammatory Effect by Inhibiting Microglial Activation Through TLR4/NLRP3 Pathway in pMCAO Rats.
Neurotox Res. 2022 Feb;40(1):259-266. doi: 10.1007/s12640-021-00447-6. Epub 2021 Nov 29.
10
A New Era in Pharmacovigilance: Toward Real-World Data and Digital Monitoring.
Clin Pharmacol Ther. 2021 May;109(5):1197-1202. doi: 10.1002/cpt.2172. Epub 2021 Feb 28.

本文引用的文献

2
Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study.
J Clin Psychiatry. 2014 Apr;75(4):362-8. doi: 10.4088/JCP.13m08433.
4
Antidepressant-induced liver injury: a review for clinicians.
Am J Psychiatry. 2014 Apr;171(4):404-15. doi: 10.1176/appi.ajp.2013.13050709.
5
Agomelatine versus other antidepressive agents for major depression.
Cochrane Database Syst Rev. 2013 Dec 17;2013(12):CD008851. doi: 10.1002/14651858.CD008851.pub2.
6
Agomelatine and hepatotoxicity: implications of cumulated data derived from spontaneous reports of adverse drug reactions.
Pharmacopsychiatry. 2013 Sep;46(6):214-20. doi: 10.1055/s-0033-1353156. Epub 2013 Aug 21.
8
Agomelatine in the treatment of fibromyalgia: a 12-week, open-label, uncontrolled preliminary study.
J Clin Psychopharmacol. 2013 Aug;33(4):507-11. doi: 10.1097/JCP.0b013e31829057ae.
9
Circadian patterns of gene expression in the human brain and disruption in major depressive disorder.
Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9950-5. doi: 10.1073/pnas.1305814110. Epub 2013 May 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验